STOCK TITAN

Veru Inc - VERU STOCK NEWS

Welcome to our dedicated news page for Veru (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veru's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veru's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
conferences covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.77%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
management covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.02%
Tags
earnings covid-19
Veru Inc

Nasdaq:VERU

VERU Rankings

VERU Stock Data

94.65M
71.68M
14.11%
40.8%
6.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Miami

About VERU

the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries